Genetic Technologies Ltd (ASX:GTG; Nasdaq:GENE) is the most active stock intra-day with over 113 million shares changing hands, although its value has eased 10.5% to $0.017.
The company has regained compliance with Nasdaq Marketplace following a deficiency notice in mid-2017.
Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment tools to help physicians proactively manage patient health.
The company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.
Adding interest and following a strategic review, the company remains in active discussions with multiple parties regarding a potential transaction.
Further details will be closely monitored by investors.
|Genetic Technologies Ltd||GTG||$0.017||-10.53%||113,744,014|
|Pancontinental Oil & Gas NL||PCL||$0.005||0%||95,747,144|
|Queensland Bauxite Ltd||QBL||$0.069||-8%||71,822,947|
|Bard1 Life Sciences Ltd||BD1||$0.016||33.33%||64,333,658|
|Atlas Iron Ltd||AGO||$0.032||-3.03%||64,299,962|
|Serpentine Technologies Ltd||S3R||$0.017||21.43%||49,188,225|
|Fatfish Internet Group Ltd||FFG||$0.100||21.95%||36,935,922|
|Kairos Minerals Ltd||KAI||$0.055||14.58%||32,602,587|